Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, BridgeBio Pharma Inc (NASDAQ: BBIO) closed at $45.9 down -1.31% from its previous closing price of $46.51. In other words, the price has decreased by -$1.31 from its previous closing price. On the day, 2.36 million shares were traded. BBIO stock price reached its highest trading level at $47.4 during the session, while it also had its lowest trading level at $45.81.
Ratios:
For a deeper understanding of BridgeBio Pharma Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.54 and its Current Ratio is at 4.57.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on July 21, 2025, initiated with a Buy rating and assigned the stock a target price of $66.
On July 14, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $70.
Oppenheimer Upgraded its Perform to Outperform on July 09, 2025, while the target price for the stock was maintained at $60.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 02 ’25 when Kumar Neil sold 40,000 shares for $42.73 per share. The transaction valued at 1,709,050 led to the insider holds 955,686 shares of the business.
Kumar Neil sold 40,000 shares of BBIO for $1,701,400 on Jul 01 ’25. The Chief Executive Officer now owns 975,686 shares after completing the transaction at $42.54 per share. On Jun 27 ’25, another insider, VIKING GLOBAL INVESTORS LP, who serves as the 10% Owner of the company, sold 3,500,000 shares for $44.00 each. As a result, the insider received 154,000,000 and left with 18,555,375 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 8715537408 and an Enterprise Value of 9526428672. For the stock, the TTM Price-to-Sale (P/S) ratio is 68.40. Its current Enterprise Value per Revenue stands at 74.767 whereas that against EBITDA is -14.376.
Stock Price History:
The Beta on a monthly basis for BBIO is 1.23, which has changed by 0.743907 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, BBIO has reached a high of $48.68, while it has fallen to a 52-week low of $21.72. The 50-Day Moving Average of the stock is 15.48%, while the 200-Day Moving Average is calculated to be 39.77%.
Shares Statistics:
For the past three months, BBIO has traded an average of 3.09M shares per day and 2605170 over the past ten days. A total of 189.83M shares are outstanding, with a floating share count of 160.86M. Insiders hold about 15.28% of the company’s shares, while institutions hold 83.49% stake in the company. Shares short for BBIO as of 1749772800 were 21119414 with a Short Ratio of 7.06, compared to 1747267200 on 22397501. Therefore, it implies a Short% of Shares Outstanding of 21119414 and a Short% of Float of 18.75.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current market rating for BridgeBio Pharma Inc (BBIO) reflects the collective analysis of 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.6, with high estimates of -$0.24 and low estimates of -$0.84.
Analysts are recommending an EPS of between -$1.94 and -$2.86 for the fiscal current year, implying an average EPS of -$2.34. EPS for the following year is -$1.87, with 5.0 analysts recommending between -$1.01 and -$2.49.
Revenue Estimates
A total of 13 analysts believe the company’s revenue will be $97.01M this quarter.It ranges from a high estimate of $198.5M to a low estimate of $55M. As of the current estimate, BridgeBio Pharma Inc’s year-ago sales were $2.17MFor the next quarter, 13 analysts are estimating revenue of $92.81M. There is a high estimate of $137.72M for the next quarter, whereas the lowest estimate is $31.89M.
A total of 18 analysts have provided revenue estimates for BBIO’s current fiscal year. The highest revenue estimate was $666M, while the lowest revenue estimate was $235.31M, resulting in an average revenue estimate of $433.38M. In the same quarter a year ago, actual revenue was $221.9MBased on 18 analysts’ estimates, the company’s revenue will be $733.83M in the next fiscal year. The high estimate is $1.88B and the low estimate is $370.29M.
